News

News Subscription

Jul 30. 2015
Basilea reports topline results of isavuconazole phase 3 study in candidemia and other invasive Candida infections
Read more
Download
Jul 24. 2015
Basilea announces that CHMP recommends approval of isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union
Read more
Download
Jun 25. 2015
Basilea initiates phase 1/2a oncology study with oral formulation of tumor checkpoint controller BAL101553
Read more
Download
May 05. 2015
Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor
Read more
Download
Apr 29. 2015
Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
Read more
Download
Apr 24. 2015
Basilea reports isavuconazole and ceftobiprole data to be presented at ECCMID
Read more
Download
Apr 01. 2015
Basilea in-licenses targeted cancer therapy
Read more
Download
Mar 07. 2015
Basilea reports U.S. FDA approval of isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis
Read more
Download
Feb 17. 2015
Basilea reports solid 2014 full-year results, preparing the ground for commercialization of Zevtera® in Europe
Read more
Download
Jan 23. 2015
Basilea announces that FDA's Anti-Infective Drugs Advisory Committee recommends approval of isavuconazole for the treatment of invasive aspergillosis and mucormycosis
Read more
Download